The Pulse
Flagship commits £100 million to build AI-native companies in UK
Flagship Pioneering has established a London lab to conceive, fund and build AI-native platform companies. It expects to recruit about 50 people and hopes partnerships will attract another £500 million.

Flagship Pioneering has committed an initial £100 million to a London lab that will create and build AI-native platform companies. The London unit, announced on November 16, is the company’s first dedicated company-creation unit outside the United States, according to its announcement.
Source prnewswire.com
Flagship Origination Lab, U.K. will conceive, test, fund and build companies working on human and planetary health, as well as other areas of science and technology. The company expects to recruit and train an initial team of about 50 scientist-entrepreneurs and operators in the UK.
Funding and company building
Founder and CEO Noubar Afeyan said Flagship anticipates using partnerships to attract an additional £500 million beyond its own initial commitment. That additional money is an expectation, rather than part of the funding already committed.
The new unit will be part of Flagship Labs, the company’s innovation foundry. It will also be connected to Flagship’s wider network, including its Pioneering Intelligence and Pioneering Medicines business units.
Avak Kahvejian, president of Flagship Labs and a general partner at Flagship Pioneering, said its company-creation work is led by teams of scientist-entrepreneurs who begin by asking what might be possible. He pointed to the UK’s science base, clinical-trial infrastructure, genomics and health-data assets, regulatory environment as reasons for the choice of location.
Earlier UK work
Flagship opened its London office and signed a memorandum of understanding with the UK government in 2023. The company said the new lab would build on three years of partnerships and research and development in the country.
The agreement set out areas for potential cooperation, including UK clinical trials and delivery, and looking for possible manufacturing locations for Flagship’s life sciences companies. It also included engagement with genomics organisations such as Genomics England, NIHR Bioresource and UK Biobank, as well as Flagship’s participation in government processes for identifying innovation opportunities.
Flagship has since launched Quotient Therapeutics, its first transatlantic company. At the time of the 2023 government announcement, Quotient had launched with $50 million and was co-anchored in the US and UK. Its work uses the study of genetic variation at the cellular level to seek links between genes and disease that can inform therapeutics.
Flagship says its UK work has also accelerated clinical trials by companies it founded, including Generate:Biomedicines, and produced partnerships across academia, data and regulatory innovation.
Flagship’s wider operation
Science, Innovation and Investment Minister Chris McDonald said the government wanted more AI and life sciences businesses to turn research and technology into jobs and growth. He said the commitment would support UK companies taking advances in those fields abroad.
Founded in 2000, Flagship says it has originated and fostered more than 100 scientific ventures. It reported $14 billion in assets under its direction as of its latest capital raise, announced in July 2024, and says its current ecosystem includes more than 40 companies, among them Moderna, Lila Sciences and Valo Health.